ABSTRACT
/L in individuals of all ages. 1 Eosinophilia is defined as an elevation of the eosinophil count, usually above 0.5 × 10 9 /L, which can be observed in a variety of conditions, including neoplastic and nonneoplastic disorders. The definition of hypereosinophilia (HE) has been well accepted as a persistent eosinophil count of at least 1.5 × 10 9 /L in the blood for at least 6 months. According to an international consensus group with modified criteria for peripheral blood and tissue HE, the subtypes of HE include hereditary (familial) HE, primary (clonal/neoplastic) HE, secondary (reactive) HE, HE of undetermined significance, and hypereosinophilia syndrome (HES). 2, 3 An individual may be considered to have HES when end-organ damage occurs because of tissue eosinophilic infiltration and release of toxic granular contents. The life-threatening organ damage may involve the heart, lungs, skin, peripheral and central nervous systems, and gastrointestinal tract.
Secondary (reactive, nonclonal) eosinophilias are the most common causes of eosinophilia. Causes include allergic disorders, such as asthma and dermatitis, parasitic and helminthic infections, and medication and drug reactions. Other less common reactive etiologies include vasculitides, neoplasms where the eosinophils are not part of the neoplastic clone, and the lymphocytic variant of hypereosinophilic syndrome (LV-HES). 4 Examples of underlying hematologic disorders in which the eosinophils are reactive include Hodgkin lymphoma, peripheral T-cell lymphomas, and B-lymphoblastic leukemia with IL3-IGH. [5] [6] [7] In these cases, the constitutive overproduction of certain cytokines is usually the primary reason leading to the peripheral eosinophilia. On the other hand, patients with eosinophilia and no apparent underlying explanation should undergo further investigation, particularly for a hematologic neoplasm. 2, 4 Primary (clonal) eosinophilia is most commonly associated with chronic myeloid neoplasms such as myeloproliferative neoplasms (MPNs) or myelodysplastic syndrome/MPNs. Less commonly, some acute myeloid leukemias, lymphoblastic leukemias, and systemic mastocytosis may occur with clonal eosinophilia. 2, 5, 8 In recognition of a subset of eosinophilias driven by constitutively activated tyrosine kinase (TK) fusion genes, genetically defined neoplasms with rearrangements of platelet-derived growth factor receptor α (PDGFRA), platelet-derived growth factor receptor β (PDGFRB), fibroblast growth factor receptor 1 (FGFR1), and Janus kinase 2 (JAK2) have been described and included in the recently updated World Health Organization (WHO) 2016 classification of hematopoietic tumors. 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Growing evidence has shown that FMS-like tyrosine kinase 3 (FLT3)-rearranged and Abelson murine leukemia viral oncogene homolog 1 (ABL1)-rearranged cases might also be associated with a myeloid and/or lymphoid neoplasm with eosinophilia, with a similar mechanism of constitutive TK activity. 12, [15] [16] [17] [18] [19] [20] Ultimately, in the event that a primary or secondary cause for the eosinophilia cannot be elucidated, a diagnosis of idiopathic hypereosinophilia (IHE) is rendered. If end-organ damage occurs because of tissue eosinophilic infiltration, the diagnosis is qualified as HES.
Given that most cases of eosinophilia are secondary (reactive), it follows that cases that require a more comprehensive examination, including bone marrow biopsy, are uncommon. However, among the latter group, the most common causes remain reactive or unexplained. Therefore, given that only a small minority of eosinophilias is clonal, it is prudent to try and tailor a workup for these cases that attains both excellent diagnostics and quality of care and maximizes appropriate test utilization.
The evaluation of patients with eosinophilia may begin with a detailed and systematic medical and travel history, physical examination, and a small selection of laboratory tests, possibly including CBC count with differential, chemistry panel, appropriate infectious disease testing, and serum tryptase level, depending on the features of a suspected disorder. 2, 3, 5 If the etiology for the eosinophilia has then yet to be unveiled, a further in-depth and often more comprehensive investigation, including bone marrow examination, is needed. Given the diversity of possibilities for eosinophilia and potential complexity of the workup, several excellent testing algorithms have been proposed by different expert professional groups. These algorithms provide guidance for the diagnostic approach, including peripheral blood and bone marrow morphologic review as an initial step. 2, 5, 6, 21 To our knowledge, however, a systematic assessment of the utility of ancillary testing results in isolated eosinophilia has not been reported in the published literature.
While there is comprehensive literature on the investigation and classification of eosinophilia, when pathologists are faced with isolated eosinophilia in an otherwise morphologically unremarkable bone marrow, the differential diagnostic considerations remain broad, and there are a wide variety of ancillary testing options from which to choose. These ancillary testing options include immunohistochemistry; flow cytometry; conventional cytogenetics; fluorescence in situ hybridization (FISH) for rearrangements of PDGFRA, PDGFRB, and FGFR1; and molecular studies for JAK2 V617F, KIT D816V mutations, and T-cell receptor gene rearrangement. Given the breadth of these ancillary study options, potential expense, and the possibility that some tests may not be routinely necessary, we aimed to retrospectively collect our institutional data regarding these ancillary studies and derive a data-driven approach to the use of ancillary tests in the workup of isolated eosinophilia cases with otherwise clinically and morphologically normal bone marrow/peripheral blood.
Materials and Methods

Case Identification, Selection Criteria, and Review
Bone marrow cases of isolated eosinophilia with otherwise unremarkable laboratory, bone marrow, and peripheral blood findings were retrospectively retrieved from our pathology database from January 2007 to September 2014. All bone marrow biopsy specimens included a peripheral blood smear, CBC count, and an adequate bone marrow specimen. The identification of these cases began with a search of our pathology database in the final diagnosis/ comment field for the term eosinophilia. All cases had a documented peripheral blood eosinophilia (>0.5 × 10 9 /L) and/or bone marrow eosinophilia of more than 5%. Most of these cases (>90%) had been heavily prescreened for secondary causes of eosinophilia and were referred for further workup to the allergy and/or eosinophilia clinics at our institution. By definition and as desired by the aim of the study, neoplastic conditions that may have eosinophilia as a typical component of their disease (eg, chronic myeloid leukemia, BCR-ABL1 positive, neoplasms with an FGFR1 rearrangement, acute myeloid leukemia with inv(16), overt systemic mastocytosis) are not included because of the presence of additional laboratory and/or morphologic abnormalities. Cases must lack any abnormalities in clinical (eg, unexplained thrombosis, splenomegaly), laboratory (eg, cytopenias, other cytoses), morphology (eg, basophilia, leukoerythroblastosis, abnormal blasts, monocytosis, abnormal lymphocytes, marked bone marrow panmyelosis, dysplasia in any of the three cell lines, abnormal megakaryocyte morphology, possible lymphoma, unexplained granulomas), or radiology (eg, lymphadenopathy) features that would otherwise prompt a pathologist and/or clinician to drive the diagnostic workup in a different and/ or more extensive direction. Such cases with any features raising concern for a diagnosable disorder were excluded upfront. Of 13 bone marrow cases harboring an FGFR1 rearrangement seen at our institution over a 21-year period (0.06% incidence), all were morphologically evident neoplasms, were chromosomally evident (with subsequent confirmation by FISH), and did not present with isolated eosinophilia. In fact, only one case exhibited concomitant eosinophilia. Similarly, we did not identify any cases (out of eight) of cytogenetically cryptic, FISH-positive, chronic myeloid leukemia, BCR-ABL1 positive that presented with isolated eosinophilia. The strict case inclusion criteria are delineated in ❚Table 1❚. The Mayo Clinic institutional review board approved this study.
Clinical and Laboratory Data
Clinical, laboratory, radiologic, pathologic, and genetic data were obtained from the electronic medical record. Clinical data abstracted from the medical record included patient age, sex, pertinent laboratory data, radiologic findings, and final integrated diagnosis. An extensive chart review and pathology report review were performed in all cases to ensure truly unremarkable clinical, morphologic, and laboratory studies. The final integrated diagnosis was established after an extensive evaluation of the medical history, clinical workup, laboratory studies, radiologic features, pathologic findings, and genetic data, in accordance with the 2016 WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, as appropriate. 7 When available, the follow-up data on the status of eosinophilia were also collected.
Pathology reports and relevant ancillary testing results corresponding to the episode of bone marrow eosinophilia were comprehensively documented. Ancillary testing results were catalogued for all cases with unexplained isolated eosinophilia, including cytogenetics, immunohistochemistry studies for tryptase/CD25/CD117, flow cytometry for T cells, FISH for BCR/ABL1 fusion and rearrangements of PDGFRA and PDGFRB, and molecular testing for JAK2 V617F, KIT D816V, and T-cell receptor gene rearrangement. To identify a more uniform cohort of isolated eosinophilia cases, it was required that each case have greater than or equal to six of the possible nine ancillary tests performed and resulted (see Supplemental Table 1 ; all supplemental materials can be found at American Journal of Clinical Pathology online).
Ancillary Studies
Immunohistochemistry
Immunohistochemical analysis was performed on 3-μm-thick, formalin-fixed, paraffin-embedded sections in all cases. A focused immunohistochemical panel was used in the evaluation of mast cells. Primary antibodies included CD25 (4C9; Cell Marque, Rocklin, CA), CD117 (YR145; Cell Marque), and tryptase (anti-human tryptase; Dako, Glostrup, Denmark).
Flow Cytometry
After isotonic erythrocyte lysis, flow cytometric immunophenotyping was performed on anticoagulated ❚Table 1❚ Inclusion Criteria for Isolated Eosinophilia Cases in Peripheral Blood/Bone Marrow 1. Documented persistent eosinophilia for ≥6 months 2. Eosinophilia >0.5 × 10 9 /L a and/or bone marrow eosinophils >5% 3. Normal peripheral blood and bone marrow morphology aside from increased eosinophils (eg, no features of basophilia, cytopenias, cytosis, dysplasia, leukoerythroblastosis, increased and/or abnormal mast cells, monocytes, increased blasts, abnormal megakaryocytes, lymphoma, panmyelosis) 4. Absence of laboratory tests, clinical and/or radiologic findings that raise concern for/require investigation for a known disorder (eg, unexplained deep-seated thromboses [possible myeloproliferative neoplasm], unexplained associated cytopenias, and/or cytoses, lymphadenopathy, skin rash) 5. Cases with clinical, morphologic, and/or laboratory features of a particular condition/set of disorders are specifically excluded (eg, clinical features concerning for myeloproliferative neoplasm, CBC count, and morphologic features of chronic myeloid leukemia, features of Hodgkin lymphoma/non-Hodgkin lymphoma)
peripheral blood or bone marrow aspirate specimens using previously described methods. 22 Samples were examined by flow cytometric immunophenotyping using a single eight-color tube for T cells containing antibodies from BD Biosciences (San Jose, CA) (CD7BB515/CD26PE/ CD2PerCPcy5.5/γδ PE-Cy7/CD5 APC/CD8 APC-H7/ CD3 APC-R700/CD4 BV421/CD45 V500) and a series of four tubes for mast cells (tube 1, IgGG1/CD117; tube 2, CD25/CD117; tube 3, CD2/CD117; tube 4, CD69/ CD117). A total of 100,000 events were collected per tube. The data were analyzed using Kaluza software (BeckmanCoulter, Brea, CA) and/or Diva software (BD Biosciences). Aberrant antigen expression was identified based on comparison with internal positive and negative controls. Mast cells were identified by bright expression of CD117.
Cytogenetic and FISH Analysis
Giemsa-banded (G-banded) chromosome analysis was performed on bone marrow samples according to conventional methods. When available, at least 20 metaphases were analyzed. Karyotypes of G-banded chromosomes were described according to the 2009 International System of Human Cytogenetic Nomenclature. 23 Abnormal clones were defined as two or more cells with the same structural abnormality, the same extra chromosomes, or the presence of three or more cells with loss of the same chromosome. Although technically clonal, cases with -Y, -X, +15, and +Y were not considered a pathologic clonal finding but regarded as an age-related phenomenon. 24, 25 FISH was performed on cell suspensions prepared from fresh bone marrow aspirate pellets using standard techniques. Probes targeting BCR/ABL1, PDGFRA, and PDGFRB gene regions were used. FISH was performed by codenaturation on a HYBrite instrument (Vysis/ Abbott, Abbott Park, IL) at a denaturation temperature of 72°C for 2 minutes for freshly dropped cells, followed by overnight hybridization at 37°C. At least 100 nuclei were examined for each probe whenever possible. Images were captured on a Leica DM5000B microscope (Leica Microsystems, Buffalo Grove, IL).
Molecular Studies
Standard BIOMED-2 Assay for T-Cell Receptor Gene Rearrangement.-T-cell receptor (TCR) gene rearrangement was analyzed using the BIOMED-2 assay (Invivoscribe, San Diego, CA). Multiplex polymerase chain reaction (PCR) for TCR gene rearrangement was performed for TCR Vβ and TCR Vγ, as described previously. 26 Standard electrophoresis visual evaluation criteria were applied for BIOMED-2 data analysis. JAK2 V617F and KIT D816V.-For JAK2 V617F, a short fragment of genomic DNA, including the mutation site, was amplified using quantitative PCR in a real-time PCR machine (LightCycler 480; Roche, Indianapolis, IN). The analytic sensitivity for detecting the JAK2 mutation was 0.05%. The analytic sensitivity for detecting the KIT mutation was 0.01%. The technique used for KIT D816V was allele-specific oligonucleotide PCR with fragment analysis on an ABI 3130xl genetic analyzer. DNA was extracted using the EZ-1 DNA kit (Qiagen, Valencia, CA).
Results
Study Cohort, General Ancillary Testing Features, and Final Diagnoses
In total, 132 bone marrow cases with isolated eosinophilia and otherwise unremarkable morphologic, laboratory, clinical, and/or radiologic features define this study cohort and were retrospectively identified. The final integrated diagnoses in the 132 cases with eosinophilia and normal-appearing bone marrow are shown in ❚Table 2❚. Of the 132 cases, 10 had an abnormal ancillary testing result(s) that warranted a specific WHO 2016 diagnostic classification 7 or other hematologic disease diagnosis: four cases of LV-HES, three cases of myeloid neoplasm with PDGFRA rearrangement, and one case each of myeloid neoplasm with PDGFRB rearrangement, chronic eosinophilic leukemia not otherwise specified (CEL NOS), and systemic mastocytosis (morphologically occult). In these 10 cases with final specific diagnoses, eight had HE (≥1.5 × 10 9 /L) at the time of biopsy. Two cases, one LV-HES and one myeloid neoplasm associated with eosinophilia and rearrangement of PDGFRA, did not have HE. In a subset of the cases with a final clinical diagnosis of IHE (n = 29), an underlying asthma (n = 20) or dermatitis (n = 9) was noted in the clinical chart. Given that this is a retrospective study, the bone marrow ancillary testing was subject to individual hematopathologist preference. This preference may include knowledge of results from prior testing, as well as the fact that translocations/rearrangements of PDGFRB and FGFR1 are generally accepted as cytogenetically evident. As such, not all nine ancillary tests were performed in all of the cases in this study cohort ❚Table 3❚. Of the 132 total cases, 41 had nine of nine, 44 had eight of nine, 30 had seven of nine, and 16 had six of nine of the ancillary tests evaluated in this study (see Supplemental Table 1 for a complete listing of each case). One remaining patient only had five of nine ancillary tests performed but is still included in this cohort because a peripheral blood study was positive for PDGFRA rearrangement, and only a limited number of additional tests were deemed necessary to be performed on the concurrently assessed bone marrow biopsy specimen.
Clinical Features and Presentation
The median age at the time of the bone marrow biopsy was 54 years (range, 11-92 years), with an equal sex distribution (52% female vs 48% male). The CBC counts showed mean levels of hemoglobin of 13.0 g/ dL (95% confidence interval [CI], 12.7-13.3), platelets of 280 × 10 9 /L (95% CI, 240-300), total WBCs of 11.2 × 10 9 /L (95% CI, 10.0-12.4), and absolute eosinophils of 3.6 × 10 9 /L (95% CI, 2.4-4.8). The mean serum tryptase level was 9.1 ng/mL (95% CI, 7.7-10.5). Eighty-five (65%) of 131 cases had HE (≥1.5 × 10 9 /L) at the time of the biopsy. Of 121 cases, 118 (98%) had at least two clinical visits for eosinophilia with an interval of 1 month or more. Seventy-five (62%) of 121 had persistent eosinophilia at their last follow-up visit (mean follow-up time 50 months with a 95% CI of 44-57 months). During the clinical course of all 132 cases, 54% had developed end-organ damage.
Bone Marrow Morphologic Features
All 132 cases in this study cohort had an adequate peripheral blood and bone marrow specimen for review. Aside from eosinophilia, review of the peripheral blood findings did not show any additional potentially abnormal features that would suggest an etiology for the eosinophilia and/or clonal disorder and drive an alternative testing strategy (eg, basophilia, neutrophilia, lymphocytosis, thrombocytosis, erythrocytosis, monocytosis, circulating blasts, leukoerythroblastic picture, cytopenias, or dysplasia). Similarly, review of the bone marrow showed no features that would suggest the possibility of a clonal disorder such as lymphoma, carcinoma, mast cell lesions, abnormal bone, granulomas, plasma cell neoplasm, dysplasia, abnormal-appearing megakaryocytes, panmyelosis, or a "packed" bone marrow. Based on available bone marrow differential counts, the median eosinophil percentage was 15% (range, 1%-50%). In the single case with less than 5% bone marrow eosinophils, the peripheral absolute eosinophil count was 1.94 × 10 9 /L.
Cytogenetic Findings
A total of 126 (96%) of 132 cases in the study cohort had conventional cytogenetics performed. Six cases had a clonal cytogenetic abnormality, three of which were considered nonpathologic and/or likely an age-related phenomenon (-Y (1), -X/+15 (1), +Y (1) [15] , respectively). In each of these three cases, the cytogenetic abnormality was considered and integrated into the final diagnosis. The case with trisomy 8 resulted in a final integrated diagnosis of CEL NOS. In the WHO 2016 revised classification, 7 it is mentioned that trisomy 8 may support a diagnosis of CEL NOS ("the finding of a recurrent karyotypic abnormality that is usually observed in myeloid disorders (e.g. gain of chromosome 8, loss of chromosome 7, or isochromosome 17q) does support the diagnosis of CEL, NOS"). While perhaps trisomy 8 Thirty-three of the remaining 39 cases were not tested for the KIT mutation because concurrent mast cell IHC stains in those cases were negative for an abnormal (spindled) and aberrant (CD25-positive) mast cell population (n = 32), and one case was positive for PDGFRA rearrangement (n = 1).
d
Three additional cases were considered nonpathologic and/or an age-related phenomenon.
may not always be diagnostic of CEL NOS, in the context of our particular case, after integrating the clinical and genetic features, our clinicians thought it best to classify as CEL NOS (despite the lack of any abnormal bone marrow morphologic features). This patient's disease was adequately controlled on hydroxyurea and prednisone before the patient was lost to follow-up after 2 years. In the case with isolated del(20q), it was thought that without additional supportive findings of a neoplastic process such as cytopenias/cytoses, dysplasia, or increased blasts, the cytogenetic abnormality by itself was insufficient for an outright diagnosis of CEL NOS. We acknowledge that this may be a controversial interpretation, but given that del(20q) is often encountered in bone marrow cases in which there is neither a diagnosable myeloid disorder by morphology nor a subsequent myeloid disorder that necessarily emerges, we thought it best to classify as IHE. This patient has been managed expectantly and is currently alive and well 4 years later without emergence of a myeloid neoplasm. The case with t(5;12)/PDGFRB rearranged was diagnosed as myeloid neoplasm with eosinophilia and PDGFRB rearrangement. 26 We recognize that it is unusual for this entity to present without other neoplastic, myeloid-appearing features but emphasize that this case highlights the importance of performing cytogenetic studies in cases of unexplained isolated eosinophilia.
FISH Testing for PDGFRA Rearrangement, PDGFRB
Rearrangement, and BCR-ABL1 Fusion
Of the 132 total cases in the study cohort, FISH was performed for PDGFRA rearrangement, PDGFRB rearrangement, and BCR-ABL1 fusion in 132, 107, and 114 cases, respectively. Testing for an FGFR1 rearrangement is available at our institution but was not routinely performed because it is not typically associated with a cryptic cytogenetic abnormality. Three (2.3%) cases were positive for a FIP1LI-PDGFRA rearrangement. All were cytogenetically normal, as expected, given that this is a cytogenetically cryptic abnormality. These three cases were ultimately diagnosed as a chronic myeloid neoplasm associated with eosinophilia and rearrangement of PDGFRA. These cases also had immunohistochemistry performed for mast cells and showed an increased, interstitial distribution of spindled mast cells, which is typical for this entity. No cases were cytogenetically normal and PDGFRB positive by FISH; no cases were cytogenetically normal and BCR-ABL1 positive by FISH. These findings argue that, in isolated eosinophilia without additional suspicious clinical, laboratory, or morphologic findings, a conventional cytogenetic study is adequate in the routine initial workup of such cases.
Immunohistochemistry for Mast Cells (Tryptase/CD25/ CD117)
Four (of 116) cases demonstrated morphologically occult, tryptase positive, individually distributed, spindled mast cells with CD25 expression. CD25 has been reported as a sensitive marker by both flow cytometry and immunohistochemistry for aberrant mast cells. 7 Three of these cases harbored a FIP1L1-PDGFRA rearrangement (as discussed in the FISH results section). The interstitial, individually distributed, spindled mast cell proliferation is well described in PDGFRA-rearranged myeloid neoplasms with eosinophilia. The fourth case was positive for the KIT D816V mutation, which, in conjunction with more than 25% mast cells with spindled morphology, met three of the four minor WHO diagnostic criteria for a diagnosis of systemic mastocytosis. 7 Of the 16 cases (out of the total 132-case cohort) that were not tested for mast cells by immunohistochemistry, 10 were negative for a KIT D816V mutation testing, arguing against occult mastocytosis since the sensitivity of the assay is less than 1% and all 16 were negative for a PDGFRA rearrangement.
Flow Cytometry for Mast Cells
Twenty-six of the study group cases had flow cytometry performed to evaluate mast cells. All cases had concurrent immunochemistry for mast cells performed (ie, no cases were evaluated for abnormal mast cells by flow cytometry alone). The single positive case by flow cytometry was also positive by immunochemistry. None of the 26 flow cytometry-negative cases were positive by immunohistochemistry.
Flow Cytometry for T Cells
Of the 122 cases evaluated for an aberrant T-cell population by flow cytometry, four (3.3%) were positive. Of these four cases, T-cell receptor gene rearrangement (TCRG) studies were clonal in two, nonclonal in one, and equivocal in one. The percentages of abnormal T cells of the total analyzed nucleated cells, as detected by flow cytometry in these four cases, were 1%, unknown, 19%, and 2% per total analyzed events, respectively. The two abnormal flow cytometry cases with clonal TCRG both exhibited a typical CD3-/CD4+ phenotype for LV-HES, which was the final integrated diagnosis in those cases. The abnormal T-cell flow cytometric immunophenotype in the equivocal TCRG case was characterized as surface CD3 positive, CD4 positive, CD2 dim positive, CD5 positive, and negative for CD7. The equivocal reading included a specific comment that a prominent peak was noted in a polyclonal background and that a true clone could not be completely excluded. Importantly, a subsequent follow-up peripheral blood TCRG evaluation (2 months later) was positive. This latter finding, in conjunction with the abnormal flow cytometry, was considered diagnostic of LV-HES. T-cell lymphoma was excluded clinically via extensive radiologic imaging, including positron emission tomography scan and multiple skin biopsies. The patient is alive and well 5 years later with no evidence of lymphoma. The abnormal T-cell flow cytometric immunophenotype in the negative TCRG case was characterized as normal intensity surface CD3, CD4, and CD5 positive with slightly diminished CD2. A reactive expansion could not be excluded based on flow cytometry and negative TCRG. T-cell lymphoma was clinically excluded based on radiologic imaging; no other pathologic specimens were obtained. These findings, taken together, were clinically thought to represent IHE, most likely associated with an autoimmune etiology.
TCRG
Of the 123 tested, nine cases had either a positive clonal result (n = 3) or an equivocal result (n = 6). Of the three TCRG clonal cases, two had abnormal flow and one had normal flow. The two cases with abnormal flow cytometry were diagnosed as LV-HES; T-cell lymphoma was excluded clinically. The third clonal case had normal T-cell flow cytometry and was thought to represent a reactive T-cell expansion. Of the six TCRG equivocal cases, one had abnormal flow and five were normal. Importantly, as mentioned in the above section ("Flow Cytometry for T Cells"), in the equivocal TCRG case with abnormal T-cell flow cytometry, a subsequent follow-up peripheral blood TCRG evaluation was positive. In the latter case, this finding was considered diagnostic of LV-HES. The final integrated diagnoses in the five cases with equivocal TCRG and normal flow cytometry were idiopathic HES (n = 3), IHE (n = 1), and reactive eosinophilia (n = 1).
JAK2 V617F Mutation Testing
Of the 99 cases tested for the JAK2 V617F mutation, no cases were positive. This finding suggests that in the absence of cytoses (in addition to isolated eosinophilia), abnormal morphology, or clinical suspicion, routine testing for the JAK2 V167F mutation is not necessary.
KIT D816V Mutation Testing
Of the 93 cases tested for the KIT D816V mutation, one case was positive. This case concurrently demonstrated an interstitial, spindled, and CD25-positive aberrant mast cell population meeting WHO criteria for a diagnosis of systemic mastocytosis (morphologically occult) (for further discussion, see the immunohistochemistry results section). All remaining 92 cases were negative. Of the 39 cases (of the total 132-case cohort) not tested for the KIT mutation, 33 (85%) had concurrent immunohistochemical testing for mast cells (tryptase and/or CD117 and CD25), and 32 were negative for an abnormal mast cell proliferation. The one positive immunohistochemical case was a known PDGFRA-rearranged myeloid neoplasm (patient 2 in Supplemental Table 1 ) in which this mast cell appearance is typical. In summary, these findings indicate that additional KIT mutation testing in cases with normal mast cell immunohistochemistry is not necessary when there is no laboratory or pathologic features to suggest an occult mast cell disease process.
Discussion
We propose an approach to ancillary test utilization for the bone marrow workup of isolated eosinophilia without any additional suspicious clinical, laboratory, radiologic, and/or morphologic features of a potentially diagnosable disorder. This approach is based on an integration of our institutional data from ancillary testing results, peer-reviewed published literature, clinician and cytogenetic experience, and national guidelines ❚Figure 1❚. The ancillary testing data derive from a cohort of 132 clinically prescreened cases of sustained unexplained isolated eosinophilia with otherwise morphologically unremarkable bone marrow. To our knowledge, this is the first study of its kind to drive a test utilization approach from institutional data in isolated bone marrow eosinophilia. While not intended to be dogmatic or exclusive of other testing, this algorithm provides a systematic initial approach to unexplained eosinophilia that, importantly, albeit in a minor subset of cases, leads to specific diagnoses and their subsequent clinically relevant and often targeted therapeutic interventions (eg, PDGFRA-rearranged myeloid neoplasm, LV-HES). [9] [10] [11] 13, [27] [28] [29] [30] This type of an approach is practical yet also comprehensive in the evaluation of key distinct diagnostic entities. 2, 5, 7 We recognize that this proposed bone marrow practice guideline is not 100% inclusive of all potential detectable (and treatable abnormalities) and is not intended to be. As information on genetic mutations and discovery of additional cytogenetically cryptic and/or therapeutic targets become available, further assessment of certain cases could be evaluated on an individualized basis.
Eosinophilia is a relatively commonly encountered phenomenon, with the primary etiology being parasitic disease in developing countries compared with allergic conditions, medications/drugs, and/or hematologic malignancies in developed countries. 4 However, despite these more common eosinophilic conditions, the complete differential diagnostic list is rather lengthy and exhaustive, including secondary (reactive) disorders (eg, allergic conditions, drugs/hypersensitivity, autoimmune disorders, hematologic and nonhematologic neoplasms), primary (clonal) neoplasms (eg, acute myeloid leukemia, chronic eosinophilic leukemia, and genetically defined myeloid/lymphoid neoplasms associated with rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2), and idiopathic eosinophilia. [1] [2] [3] [4] [5] [6] [7] [8] [31] [32] [33] [34] Given this broad range of underlying disease possibilities with treatments that vary from removal of the offending agent to chemotherapy to targeted tyrosine kinase inhibitors, it is imperative that there be a comprehensive yet concise diagnostic approach. 30, [35] [36] [37] [38] Advances in our understanding of the scientific basis for hematologic diseases, including eosinophilias, have resulted in an increased number of analytically complex and expensive diagnostic laboratory tests that are available for routine clinical practice. Because of this progress, it is important to ensure that the correct testing is being performed. For example, rearrangements of PDGFRA and PDGFRB in hematologic neoplasia are exquisitely sensitive to treatment with tyrosine kinase inhibitors (TKIs), whereas the KIT D816V mutation in mastocytosis is resistant to TKIs. 27, 31, [33] [34] [35] [36] [37] [38] This increased number of complex tests can make it difficult for practicing physicians to know which tests to choose (or not) to help solve diagnostic problems efficiently. Similarly, information may be limited about the sequence in which the tests should be performed to address the differential diagnostic possibilities for hematologic disorders.
For eosinophilic disorders, several excellent testing guidelines incorporating the WHO classification 7 of hematopoietic neoplasms have been published and include consideration of a possible hematologic neoplasm with clonal eosinophilia. 2, 5, 6, 39 In this study, we used our institutional clinical practice data, in conjunction with known peer-reviewed published literature and accepted guidelines, to derive an algorithmic bone marrow testing approach in our clinical practice for otherwise unexplained isolated eosinophilia (Figure 1 ). The study herein focuses specifically on cases that lack clinical, laboratory, radiologic, and/or pathologic features that are otherwise suspicious or worrisome for a particular disease entity/ etiology. In the latter situations, initial ancillary testing is generally targeted and driven toward investigation of the suspected disease (eg, BCR-ABL1 testing for possible chronic myeloid leukemia [CML] , immunophenotypic studies for lymphoma).
From our cohort, we were able to demonstrate the utility of several ancillary tests in isolated eosinophilia to evaluate for potential morphologically occult-specific disease entities (PDGFRA-rearranged eosinophilia, LV-HES, PDGFRB-rearranged eosinophilia, mastocytosis, and CEL NOS). These ancillary tests may include FISH for the PDGFRA rearrangement (which is almost always karyotypically cryptic), flow cytometry for an abnormal T-cell population, immunohistochemistry for an abnormal mast cell infiltrate mutation, and conventional cytogenetics for a clonal abnormality, respectively (Figure 1) . In our experience, it is not necessary, in the absence of other suspicious morphologic, clinical, or CBC features, to perform JAK2 mutation testing, BCR-ABL1 FISH, or PDGFRB FISH. Although not directly addressed in this study, based on current published literature, FISH for FGFR1 rearrangement and JAK2 rearrangement does not need to be routinely performed upfront because these genetic abnormalities are typically recognized by experienced cytogeneticists and are detectable on routine cytogenetic studies. When suspected cytogenetically, FISH for the particular genetic locus is useful to confirm the involved genetic target.
Our proposed eosinophilia pathology testing algorithm shares several similarities with the published literature and currently published guidelines. This includes a significant upfront investment in the initial assessment for a known or unknown external cause for the eosinophilia (eg, hypersensitivity reaction, allergy/atopic disorder, autoimmune condition, drug/medication, infection, known causative disorder, neoplasm or association) and any specific/targeted testing that may be needed. In effect, these evaluations attempt to exclude readily identifiable causes of secondary eosinophilias from unnecessary further workup and testing. Other similarities, when the eosinophilia is sustained and unexplained, include recommendations for PDGFRA rearrangement testing by FISH and/or molecular assay for abnormal T-cell population testing by flow cytometry to evaluate for the LV-HES, for abnormal mast cell immunohistochemistry for mastocytosis, and for karyotyping for chronic eosinophilic leukemia. 2, 5, 8, 10, 39 It is well known that the PDGFRA rearrangement is a cryptic cytogenetic abnormality and exquisitely responsive to imatinib (TKI) and thus should be assessed in the initial workup panel of otherwise unexplained isolated bone marrow eosinophilia. [9] [10] [11] 13, 14, [28] [29] [30] In addition, the LV-HES should also be systematically assessed by flow cytometry given the marked improvement in symptoms after corticosteroid therapy.
Some differences in our study are noted, however, with the published literature with respect to testing for JAK2 V617F mutation, BCR-ABL1 fusion, and FISH for rearrangement of PDGFRB. In the setting of eosinophilia with otherwise morphologically unremarkable bone marrow (absence of basophilia, monocytosis, increased blasts, abnormal megakaryocytes, dysplasia, abnormal lymphoid infiltrates, etc), we did not find that JAK2 V617F and BCR-ABL1 testing are routinely necessary. No isolated eosinophilia cases harbored a JAK2 V617F mutation or BCR-ABL1 fusion. Given the criticality of identifying the BCR-ABL1 fusion, both for proper classification and for targeted therapy, we also searched our genetic files over a 7-year period for cases of cytogenetically cryptic, BCR-ABL1-positive CML cases. Of eight cryptic CML cases, none were characterized morphologically by isolated eosinophilia, arguing that one is not inclined to miss a significant number of these theoretically rare cases.
Similarly, from our experience and the published literature, rearrangements of PDGFRB (5q32), FGFR1 (8p11.23), and JAK2 (9p24.1) in isolated eosinophilia are not generally regarded as cytogenetically cryptic in the setting of good-quality metaphases. Rarely, abnormalities of PDGFRB may be cytogenetically cryptic. 41 This is important, particularly in the context of an algorithmic approach, as additional submicroscopic abnormalities that may be sensitive to treatment with TKIs and/or other targeted therapies are discovered. Such discoveries will drive continued reassessment of our evaluation of these types of cases with regard to bone marrow ancillary testing. Furthermore, the recent literature indicates that a small subset of patients with HE has responded to the TKI imatinib without an identified target. This suggests the possibility of a subset of cases with cryptic abnormalities that have yet to be discovered. 42, 43 In addition, Wang et al 21, 44 recently demonstrated in two separate reports that abnormal bone marrow morphology is a strong indicator of chronic eosinophilic leukemia vs IHE cases and that IHE with abnormal morphologic features is similar to chronic eosinophilic leukemia using targeted next-generation sequencing techniques. Studies such as these highlight the importance of abnormal morphologic features in the upfront evaluation of eosinophilia. In such instances, specialty testing should be driven by the abnormal features and suspected diagnosis.
In summary, our findings support a judicious ancillary test utilization approach for the workup of isolated bone marrow eosinophilia (Figure 1 ). This stepwise approach, in conjunction with known relevant clinical, laboratory, and radiologic features, helps achieve test utilization efficiency and diagnostic effectiveness in routine clinical practice. There are well-accepted limitations in the application of algorithmic approaches-mainly, that they are intended to meet the needs of 80% to 90% of cases. Exceptions are expected and handled on a case-by-case basis. This proposed approach is based on data derived from a large cohort of cases at our institution and provides guidance for an effective starting point for persistent and unexplained eosinophilia with otherwise morphologically unremarkable bone marrow.
